12-01-2004: Bron DOW-Amerika
Provenge, een immunotherapeutisch middel scoort 3,5 x langere overlevingstijd (30,7 maanden gemiddelde overlevingstijd tegenover 22,3 oftewel log rank p = 0.047, hazard ratio = 1.89) bij vergevordere prostaatkanker met Gleasonscore onder de 7, aldus vandaag gepubliceerde dubbelblinde gerandomiseerde fase III studieresultaten. Dendreon organiseert nu wereldwijd meerdere fase III trials met Provenge voor prostaatkankerpatiënten waarvan de Gleasonscore onder de 7 ligt, maar waar de prostaatkanker ondanks de hormoontherapie verder doorgroeit. Dus laten we hopen dat in Nederland snel enkele ziekenhuizen deze aanpak zullen aanbieden aan prostaatkankerpatiënten. 

-- PRESS RELEASE: Dendreon's Provenge Extends Survival in Advanced Prostate Cancer -- SEATTLE--(BUSINESS WIRE)--Jan. 12, 2004--

Results from ongoing monitoring of Company's completed D9901 Phase 3 trial is longest survival benefit seen in late-stage prostate cancer
Dendreon Corporation (Nasdaq:DNDN) today announced updated survival data from patients with advanced prostate cancer with Gleason Scores of seven and less who participated in its completed and previously reported Phase 3 trial (D9901) of Provenge(R), the Company's investigational immunotherapy for the treatment of prostate cancer.
Patients with Gleason Scores of seven and less receiving Provenge had a significant survival advantage, having on average an 89 percent overall increase in their survival time as compared to placebo (log rank p = 0.047, hazard ratio = 1.89). This benefit is reflected by a prolongation in the median survival time in patients receiving Provenge by 8.4 months (30.7 months versus 22.3 months).
At 30 months from randomization, the survival rate for Provenge-treated patients is 3.7 times higher than for patients receiving placebo (53 percent versus 14 percent, p = 0.001).
Consistent with previous reports, a majority of those patients in D9901 who are still alive have received treatment with Provenge and will continue to be followed according to the study protocol. The Company expects to present this as well as other updated data at major scientific meetings throughout the year.
Prostate cancer is the most common non-skin cancer in the United States. More than one million men in the United States have prostate cancer, with an estimated 220,000 cases diagnosed and 28,900 deaths in 2003.
"This is the longest survival benefit ever reported in a Phase 3 study in late stage prostate cancer," said Dr. John M. Corman Director of the Virginia Mason Comprehensive Prostate Cancer Clinic and Assistant Clinical Professor of Urology at the University of Washington in Seattle. "With the combination of this exciting new survival data and favorable side effect profile, Provenge has the potential to change the way we treat prostate cancer in the future."
These updated survival data are consistent with other previously reported data from the D9901 trial that showed significant clinical benefit from Provenge treatment for men with a Gleason Score of seven and less. For these men, the average time to disease progression is more than two-fold longer than that for patients treated with placebo (p = 0.001) and the average time to experiencing cancer-related pain is more than 2.5 times longer than that for patients treated with placebo (p = 0.016). Treatment was well tolerated, with mild infusion-related fevers and chills the most common adverse events. As previously reported, no benefit has been seen in men with Gleason Scores of eight and higher.
Last year, Dendreon also released data confirming Provenge's mechanism of action based on T-cell mediated immune response. These data showed that among men treated with Provenge, those with a Gleason Score of seven and less demonstrated a T-cell mediated immune response 7-fold greater than men with a Gleason Score of eight or more (p = 0.0065).
"Based on the strength of this survival data, which is consistent with all of the data gathered to date on our other endpoints in the trial for patients with Gleason Scores of seven and less, we are more enthusiastic than ever regarding the pivotal role that Provenge may play in providing a new and well tolerated targeted therapy for prostate cancer patients," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "The results from this study represent an important milestone in the fight against prostate cancer and indicate that Provenge may provide for a well-tolerated treatment option that offers patients a potential survival advantage."
The ongoing, pivotal D9902B Phase 3 trial of Provenge is based on the knowledge gained from the results of D9901. The study is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Provenge also has Fast Track designation. The pivotal double blind, placebo-controlled D9902B trial is now underway at leading cancer centers around the country. To be eligible for the study, patients must have metastatic prostate cancer that has progressed following hormone therapy and have a Gleason Score of seven and less. Patients must also be free of cancer-related pain. 

About Provenge
Provenge is designed to stimulate a man's immune system against prostate cancer. It is developed through Dendreon's proprietary Antigen Delivery Cassette(TM) technology, which utilizes a recombinant form of an antigen found in 95 percent of prostate cancers, prostatic acid phosphatase (PAP).

About Gleason Score
The Gleason Score is the most commonly used prostate cancer scoring system and is considered one of the most important prognostic indicators for prostate cancer. The score is based on tissue findings throughout the prostate that correlate with the aggressiveness of a tumor. High Gleason Scores are indicative of aggressive cancers and are not associated with a favorable prognosis. In the androgen independent patient population approximately 75 percent of the patients have a Gleason Score of seven and less.

Plaats een reactie ...

Reageer op "Dubbelblinde gerandomiseerde fase III studie bewijst uitstekend effect van Provenge. 3,5 keer langere overlevingstijd en minder pijn."

Gerelateerde artikelen

Gerelateerde artikelen

Afro-Amerikanen met uitgezaaide >> immuuntherapie met Provenge >> Provenge, het eerste immuuntherapeutische >> Provenge - Sipuleucel-T, vaccinatie >> Het vaccin Provenge zorgt >> Provenge als immuuntherapie >> Provenge,- Sipuleucel-T, het >> Driejaars meting van fase >> Dubbelblinde gerandomiseerde >> Provenge een immuuntherapie >>